首页> 外文期刊>RSC Advances >Chloro-aluminium phthalocyanine loaded in ultradeformable liposomes for photobiology studies on human glioblastoma
【24h】

Chloro-aluminium phthalocyanine loaded in ultradeformable liposomes for photobiology studies on human glioblastoma

机译:氯铝酞菁,用于对人胶质母细胞瘤的光生物学研究的超无关脂质体

获取原文
获取外文期刊封面目录资料

摘要

Photodynamic therapy (PDT) has emerged as an alternative clinical protocol to treat brain tumors in early and advanced stages. PDT has provided promising results in both in vitro and in vivo (animal) studies. Phthalocyanines (Pcs), classified as second-generation photosensitizers (PSs), display advantageous photophysical properties and have been recognized as potential PSs for PDT. Because Pcs absorb strongly in the red region of the electromagnetic spectrum (670–780 nm), have low dark toxicity, efficiently generate ROS, and selectively target tumors in a well-designed drug delivery system (DDS), these photosensitizers have been applied for industrial, technological, and medical purposes. In this study, we have loaded chloroaluminum phthalocyanine (PcAlCl) in ultradeformable liposomes (UDLs) of soybean phosphatidylcholine containing different edge activators (Tween 80, Span 80, sodium desoxycholate) as a DDS. We have also compared the photo and physicochemical characteristics of these UDLs with the characteristics of classic and well-established conventional liposomes (CLs) currently used as DDS for different drugs in many pharmaceutical industries. The UDLs measured between 78 and 142 nm on average, presented zeta potentials between ?6.1 and ?39.9 mV, had encapsulation efficiencies ranging from 50.3 to 84.7%, and remained stable for 12 months. The elasticity of the UDLs resulted in two to four times higher stability as compared to CLs, a major advantage for pharmaceutical applications. The UDLs were not cytotoxic in dark conditions (IC _(50) > 2.0 μM); however, their viability decreased significantly 24 hours post-irradiation with any of the visible light doses used herein. The light dose that gave the best activity was 1 J cm ~(?2) . Compared to free PcAlCl, PcAlCl loaded on UDLs exhibited 72% higher activity toward the glioblastoma cell line U87MG (ID _(50) = 0.4 J cm ~(?2) ) and the cell death mechanism was based on apoptosis. These data reinforced the idea that UDLs are an efficient DDS for PcAlCl during PDT treatment of brain cancer cells.
机译:光动力疗法(PDT)已成为替代临床方案,以在早期和高级阶段治疗脑肿瘤。 PDT在体外和体内(动物)研究中提供了有希望的结果。分类为第二代光敏剂(PSS)的酞菁(PC),显示有利的光性特性,并且已被认为是PDT的潜在PSS。因为PC在电磁频谱的红色区域(670-780nm)中强烈吸收,所以具有低暗毒性,有效地产生ROS,并在设计精心设计的药物输送系统(DDS)中选择性地靶向肿瘤,这些光敏剂已被施加工业,技术和医学目的。在该研究中,我们在含有不同边缘活化剂(吐温80,跨度80,脱氧胆酸钠)中的大豆磷脂酰胆碱的超不可形成的脂质体(UDL)中加载氯铝酞菁(PCALCL)。我们还将这些UDL的照片和物理化学特性与当前用作许多药物行业中不同药物的DDS的经典和良好的常规脂质体(CLS)的特征进行了比较。在78和142nm之间测量的UDL平均呈现Zeta电位(Δ6.1和β39.9mV,封装效率范围为50.3%至84.7%,并保持稳定12个月。与CLS相比,UDL的弹性导致稳定性更高两至四倍,该稳定性是药物应用的主要优点。在暗条件下,UDL不是细胞毒性(IC _(50)>2.0μm);然而,与本文所用的任何可见光剂量的照射后,它们的活力明显减少了24小时。给出了最佳活性的光剂量为1 J cm〜(?2)。与游离PCALCL相比,加载ON UDL上的PCALCL向胶质母细胞瘤细胞系U87mg(ID _(50)= 0.4J cm〜(β2))表现出72%的活性,并且细胞死亡机制基于凋亡。这些数据增强了UDL在脑癌细胞的PDT治疗过程中为PCALC1的高效DDS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号